January 19, 2000
ImmunoGen, Inc. Reports Second Quarter Results

NORWOOD, Mass., Jan. 19 /PRNewswire/ -- ImmunoGen, Inc. (Nasdaq: IMGN) today announced financial results for the second quarter ended December 31, 1999. For the three-month period ended December 31, 1999, the Company reported net earnings to common stockholders of $105,000, or less than $0.01 per diluted share, compared to a net loss to common stockholders of ($1,637,000), or ($0.06) per basic and diluted share, in the same quarter last year. For the six-month period ended December 31, 1999, the Company reported net earnings to common stockholders of $1,855,000, or $0.06 per diluted share, compared to a net loss of ($4,096,000), or ($0.16) per basic and diluted share, for the same period last year. The profits in both the three and six- month periods ended December 31, 1999 were driven largely by milestone payments in connection with the Company's collaboration with SmithKline Beecham plc (SB) to develop and commercialize huC242-DM1/SB-408075, the Company's Tumor Activated Prodrug for the treatment of colorectal, pancreatic and non small-cell lung cancers.

"Our second quarter results reflect a $2.5 million milestone payment received from SB on initiation of our Phase I clinical study of huC242-DM1/SB- 408075. In less than one year since execution of our agreement with SB, we have achieved four milestones and received a total of $12.0 million," stated Mitchel Sayare, Ph.D., Chairman and CEO of ImmunoGen, Inc. "We began clinical trials of huC242-DM1/SB-408075 this quarter, while we continue to aggressively pursue partners to develop other product candidates."

ImmunoGen, Inc. develops innovative biopharmaceuticals, primarily for cancer treatment. The Company has created potent tumor-activated prodrugs, consisting of drugs coupled to monoclonal antibodies, for delivery to and destruction of cancer cells.

This press release includes forward-looking statements based on management's current expectations. Factors that could cause future results to differ materially from such expectations include, but are not limited to: the ability to secure future funding; the success of the Company's research strategy; the applicability of the discoveries made therein; the difficulties inherent in the development of pharmaceuticals, including uncertainties as to the timing and results of preclinical studies; delayed achievements of milestones; reliance on collaborators; uncertainty as to whether the Company's potential products will succeed in entering human clinical trials and uncertainty as to the results of such trials; uncertainty as to whether adequate reimbursement for these products will exist from government, private healthcare insurers and third-party payors; and the uncertainties as to the extent of future government regulation of the pharmaceutical business.



The "Yes" link below will take you out of the AbbVie family of websites.

Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.

The Internet site that you have requested may not be optimized to your screen size.

Do you wish to leave this site?